

The underlying condition of the patient at admission was accidental trauma in 4/14 (28.7%) chronic kidney disease in 2/14 (14.2%), hematological malignancy in 2/14 (14.2%), pneumonia in 1/14 (7.1%), retroviral disease in 1/14 (7.1%), acute febrile illness in 1/14 (7.1%). The risk factors for acquisition of infections with *Trichosporon* species in the 14 patients were administration of broad-spectrum antibiotics in 13 (92.8%), urinary catheterization in 11 (78.5%), central venous catheterization, and prolonged ICU stay in 8 (57.1%) each, previous antifungal therapy in 6 (42.8%). The other risk factors were chemotherapy, steroid usage, and neutropenia.

The clinical presentations were urinary tract infections in 10/14 (71.4%) patients (9 were catheter-associated UTIs), fungemia in 2/14 (14.2%), and wound infections in 2/14 (14.2%) patients.

*Trichosporon asahii* is the predominant species isolated in 12/14 (85.7%) patients. Other *Trichosporon* spp. isolated include *T. inkin* and *T. dobaense*. All the isolates were correctly identified by VITEK 2 except one which was identified as *T. inkin* in VITEK 2 and *T. dobaense* by MALDI-TOF.

All the isolates were susceptible to voriconazole and amphotericin B. 9/14 (64.2%) of the isolates were susceptible to fluconazole. *Trichosporon* spp. is inherently resistant to echinocandins.

A total of 7 patients (50%) were successfully treated with voriconazole for a period of 14 days with advice to follow up and discharged. In all, 5 patients (35.7%) died due to underlying diseases before treatment could be started.

Conclusion: Urinary tract infection, mostly CA-UTI was the commonest clinical presentation of Trichosporonosis in our study followed by bloodstream infection and wound infection. The commonest risk factor was prolonged broad-spectrum antibiotic therapy followed by urinary catheterization. The growth of *Trichosporon* spp. from various samples has to be interpreted with caution as the organism can also exist as a colonizer in different body sites. Voriconazole was effective in the treatment of trichosporonosis.

## P255

### Facial Tinea incognito: a clinical, dermoscopic, and mycological study

Jin Park, Sang-Kyung Lee, Kyung-Hwa Nam, Seok-Kweon Yun  
Department of Dermatology, Jeonbuk National University Medical School, Jeonju, South Korea

Poster session 2, September 22, 2022, 12:30 PM - 1:30 PM

Objectives: Tinea incognito (TI) occurring on the face is the most frequently misdiagnosed cutaneous fungal infection; however, very limited information is available on facial TI. This study aimed to characterize the clinical, dermoscopic, and mycological features of facial TI.

Methods: We retrospectively evaluated 38 patients with mycologically proven facial TI at a single institution in Korea between July 2014 and July 2021.

Results: The patients had a mean age of  $59.6 \pm 20.4$  years and showed a slight female predominance (male-to-female ratio, 1:1.5). The most common clinical presentation was an eczema-like pattern (47.3%), followed by rosacea-like (15.7%), psoriasis-like (10.5%), lupus erythematosus-like (10.5%), cellulitis-like (7.8%), and folliculitis-like (7.8%) patterns. The mean duration from disease onset to diagnostic confirmation was 3.4 months. Overall, 78.9% of the patients had accompanying chronic systemic diseases and 57.9% had concurrent tinea infections on other skin sites, mainly on the feet and toenails. Among the 23 (60.5%) cultured specimens, *Trichophyton (T.) rubrum* was the most frequently detected causative species, followed by *Microsporum (M.) canis*. *T. mentagrophytes* and *T. verrucosum* were also isolated from one case each. On dermoscopy, scales (92.1%) and dilated vascular patterns (arborizing vessels and telangiectasia, 76.3% and 63.2%) were commonly observed in glabrous skin, with follicular patterns such as black dots, broken hairs, and empty follicles. The characteristic trichoscopic features were comma hairs, corkscrew hairs, Morse code-like hairs, and translucent hairs.

Conclusion: The clinical characteristics and distinct dermoscopic features described in this article can aid in the differential diagnosis of facial TI while reducing diagnostic delays and unnecessary treatments.

## P256

### A rare case of co-infection with *Nigrospora oryzae* with mucormycosis in an immunocompromised post-COVID patient

Ankita Patel, Alisha Sharma, Pooja Mahajan, Ashish Bahal, Sandeep Ninawe, Puneet Bhatt, Naveen Grover  
Army Hospital Research & Referral, New Delhi, India

Poster session 2, September 22, 2022, 12:30 PM - 1:30 PM

Objective: A rare case of co-infection of *Nigrospora oryzae* with mucormycosis in an immunocompromised post-COVID patient.

Methods: A 41-year-old male diabetic patient, with sub-optimal glycemic control, contracted COVID-19 infection and was managed with high-dose steroids. A month after recovery from COVID-19 infection, he developed severe headache with sudden onset right-sided facial swelling. A contrast-enhanced magnetic resonance imaging was done which was suggestive of infective/inflammatory rhinosinusitis with intracranial extension with a possibility of fungal etiology. Functional endoscopic sinus surgery was performed and tissue was sent for microbiological processing. On KOH mount, broad pauciseptate fungal hyphae were seen. Fungal growth was obtained on SDA at 25°C and 37°C within 4 days of inoculation. It was confirmed as *Rhizopus arrhizus* both phenotypically as well as by MALDI-TOF. Patient was put on antifungal therapy in form of Inj liposomal Amphotericin B 500 mg/d. However, patient had persistent headache, vomiting, and low-grade fever post-procedure. A repeat CE-MRI was performed which was suggestive of necrotic brain tumor/abscess and was planned for frontal lobe abscess drainage. Pus was inoculated on routine mycological media. On KOH mount, broad pauciseptate hyphae along with narrow septate hyphae were seen. Fungal growth was obtained on SDA at 25°C within 5 days of inoculation, which on LPCB were identified as *Nigrospora* spp. The identity of the isolate was confirmed by Next generation sequencing as *Nigrospora oryzae*. Post-2 weeks of treatment and strict glycemic control, patient started improving. The headache and swelling subsided. He was further started on oral hypoglycemic agents and discharged and was asked to follow up after a month.

Results: COVID-19 epidemic that emerged by the end of 2019 has been associated with a huge number of deaths globally. Acute invasive fungal rhino-sinusitis is a potentially fatal infection in immune-compromised patients post COVID-19. Various studies reveal that invasive fungal infections have been the leading cause of death in 25%-73.7% of patients. Among these invasive fungal infections, *Mucor* spp. were detected in 77.8% patient, *Aspergillus fumigatus* in 30.6% while 8.3% showed mixed infection with both the fungi. Along with the established pathogenicity of Mucorales in causing invasive fungal infection, other fungal co-infections are also being observed. These invasive fungal infections in an immune-compromised host carry a high mortality and morbidity rate (18%-80%). Therefore, early diagnosis, followed by aggressive medical care, surgical debridement, and control of underlying diseases is of utmost importance.

Conclusion: Acute invasive fungal rhinosinusitis saw a spurt in incidence during the widespread COVID-19 pandemic.

Diagnosis of invasive fungal infection is based on the clinical setting and characteristic presentation, supported by radiological and microbiological evidence. Prompt diagnosis and treatment are the need of the hour.